BioCentury
ARTICLE | Clinical News

Coprexa: Pivotal trial data

November 13, 2006 8:00 AM UTC

In a double-blind, pivotal trial in 48 patients, Coprexa met the primary endpoint of a statistically significant reduction in incidence of neurologic worsening vs. Syprine trientine (4% vs. 26%, p<0.0...